[Skip to Content]
[Skip to Content Landing]
Views 725
Citations 0
Comment & Response
May 1, 2018

Quality of Life in Patients With Glioblastoma Treated With Tumor-Treating Fields—Reply

Author Affiliations
  • 1Malnati Brain Tumor Institute, Northwestern University, Chicago, Illinois
  • 2Department of Neurosurgery, Tel Aviv Medical Center, Tel Aviv, Israel
JAMA. 2018;319(17):1823. doi:10.1001/jama.2018.1862

In Reply Our randomized trial demonstrated a consistent improvement in both progression-free and overall survival when TTFields was included in first-line therapy for glioblastoma. The hazard ratio for death was 0.63, translating into an improvement in the 2-year survival rate from 31% to 43%. For comparison, the addition of temozolomide to radiotherapy compared with radiotherapy alone also resulted in a hazard ratio of 0.63, with a 2-year survival rate increasing from 10% to 27%.1 One may consider the improvements modest, yet these are the most effective proven treatments available.